BIO Worried CMS’ Alzheimer’s Coverage Is ‘Trial Balloon’ For Lower Accelerated Approval Reimbursement

 
• By Sarah Karlin-Smith
  
colorful balloons
BIO is concerned about future drug reimbursement challenges due to CMS’ view of accelerated approval. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access